title: Ruxolitinib and survival improvement in patients with myelofibrosis.
authors.affiliation: Division of Hematology, Department of Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Passamonti
authors.affiliation: Section of Hematology, Department of Critical Care, University of Florence, Florence, Italy.
authors.forename: A M
authors.initials: AM
authors.lastname: Vannucchi
authors.affiliation: Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Cervantes
authors.affiliation: Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK.
authors.forename: C
authors.initials: C
authors.lastname: Harrison
authors.affiliation: Division of Hematology, Ospedale Niguarda Cà Granda, Milano, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Morra
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: H
authors.initials: H
authors.lastname: Kantarjian
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: S
authors.initials: S
authors.lastname: Verstovsek
mesh_terms: D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000401:mortality*; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D011720:Pyrazoles; D053612:Janus Kinases